Answers are grounded in this paper and cite their sources.
Antibody purification is key to advancing immunotherapy, but high costs in traditional affinity chromatography remain a barrier. In response, we present a breakthrough technology for purifying antibodies from human blood plasma (HBP) and cell culture supernatant using a potential-controlled method. This innovative platform applies an electrical potential to efficiently elute up to 95% of bound antibodies from Protein A affinity membranes at optimal voltages of +2.5 to 3 V, all without the need for buffer exchange. Antibody quality, analyzed via Dynamic Light Scattering (DLS), Size-Exclusion Chromatography (SEC) with Multi-Angle Light Scattering (SEC-MALS), and Surface-Plasmon-Resonance (SPR), demonstrated superior retention of antibody integrity. Our potential-controlled affinity membrane chromatography (PCAMC) offers a revolutionary alternative to traditional techniques, boosting efficiency and sustainability while overcoming the limitations of conventional affinity methods. This study sets the stage for a cost-effective and eco-friendly future in antibody therapeutics.
No takes yet. Share an insight, caveat, or question.
Steegmüller et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: